When was Enzymotec founded?

Enzymotec was founded in 1998 and raised its 1st funding round 11 years after it was founded.

Where is Enzymotec located?

Enzymotec is headquartered in Kfar Saba, Israel.

How many employees does Enzymotec have?

As of Mar 01, 2026, the latest employee count at Enzymotec is 50 - 199.

Is Enzymotec a funded company?

Enzymotec is a funded company, having raised a total of $21M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Feb 03, 2009.

When was the latest funding round of Enzymotec?

Enzymotec's latest funding was a $***** Post IPO round on Aug 01, 2017, with participation from 1 investor.

Where does Enzymotec rank among its competitors?

Enzymotec ranks 3rd amongst 102 active competitors, of which 9 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was All G, which secured $6.6M in Dec, 2025.

Who are the top competitors of Enzymotec?

Enzymotec's top competitors include The DuPont Nutrition and Health, Zivo Bioscience and Kyowa Hakko Bio. Among them, All G secured the most recent funding round in December, 2025.

Enzymotec - 2026 Company Profile, Funding & Competitors

Q: Is Enzymotec an acquired company?

Enzymotec got acquired by Frutarom on Oct 28, 2017.

Enzymotec is an acquired company based in Kfar Saba (Israel), founded in 1998. It operates as a Bio-functional lipid ingredients and final products for nutritional and pharmaceutical application. Enzymotec has raised $21M in funding from investors like Ofer-Hi Tech, Millennium Materials Technologies Fund and Galam. The company has 102 active competitors, including 9 funded and 17 that have exited. Its top competitors include companies like The DuPont Nutrition and Health, Zivo Bioscience and Kyowa Hakko Bio.

Company Details

Enzymotec develops and produces biofunctional ingredients to address health needs associated with the human life cycle, starting from babies up to seniors. It develops, manufactures and markets bio-functional lipid ingredients, as well as final products, based on proprietary processes and technologies. Offerings encompass two segments - Nutrition ingredients for infant formulas and dietary supplements (sold through Advanced Lipids, our joint venture with AAK) and branded lipid-based medical foods for the dietary management of medical disorders and phospholipid-based bioactive ingredients for nutritional supplements. Other nutritional ingredients include krill oil and dietary supplements targeted at improving brain health providing benefits in memory, learning abilities and concentration. Enzymotec subsidiary Vaya Pharma manufactures lipid-based products for addressing dietary issues in Attention Deficit Hyperactivity Disorder (ADHD) and Hypertriglyceridemia.

Website: enzymotec.com
Social

Key Metrics

Founded Year

1998

Location

Kfar Saba, Israel

Stage

Acquired

Total Funding

$21M in 3 rounds

Latest Funding Round

Post IPO, Aug 01, 2017, $*****

Investors

Ofer-Hi Tech & 10 more

Ranked

3^rd among 102 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Investment & Acquisitions

Union Springs Healthcare

Similar Companies

The DuPont Nutrition and Health & 116 more

Exit Details

Acquired by Frutarom (Oct 28, 2017)

View Enzymotec's full profile

Enzymotec got acquired by Frutarom on Oct 28, 2017 at an acquisition amount of $*****.

Click here to take a look at Enzymotec's acquisition in detail

Enzymotec has raised a total funding of $21M over 3 rounds. Its first funding round was on Feb 03, 2009. Its latest funding round was a Post IPO round on Aug 01, 2017 for $*****. 1 investor participated in its latest round. Enzymotec has 11 institutional investors.

Here is the list of recent funding rounds of Enzymotec:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2017	9878416	Post IPO	9163350	9835415	8939839	9704842
Jan 03, 2012	7446845	Series B	4115888	1185393	1451786	1265726
Feb 03, 2009	4852705	Series B	6863934	9773007	Ofer-Hi Tech & 2 more	Arancia

Access funding benchmarks and valuations. Sign up today!

View details of Enzymotec's funding rounds and investors

Enzymotec's employee count trend

Enzymotec has 50 - 199 employees as of Mar 26. Here is Enzymotec's employee count trend over the years:

Uncover Enzymotec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enzymotec include The DuPont Nutrition and Health, Zivo Bioscience and Kyowa Hakko Bio. Here is the list of Top 10 competitors of Enzymotec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	The DuPont Nutrition and Health 1989, Copenhagen (Denmark), Acquired	Manufactures a range of health ingredients	$880K	Impact Fund Denmark, OSTI	56/100
2nd	Zivo Bioscience 1983, Keego Harbor (United States), Public	Algae-based nutritional compounds and bioactive molecules for animal and human health	$962K	Veyo Partners, Centrecourt Asset Management ... & 2 others	50/100
3rd	Enzymotec 1998, Kfar Saba (Israel), Acquired	Bio-functional lipid ingredients and final products for nutritional and pharmaceutical application	$21M	BIP Investment Partners, XT Hi-Tech & 9 others	49/100
4th	Kyowa Hakko Bio 2008, Chiyoda City (Japan), Acquired	Manufacturing and marketing a range of nutraceutical ingredients	-	-	49/100
5th	Nexira 1895, Rouen (France), Late Stage	Manufacturer of natural ingredients for food, health and nutrition	-	Andera Partners	47/100
6th	DE3PBIO 2018, Middletown (United States), Seed	Developer of active functional ingredients for food, nutraceutical, beauty applications	$9.08M	DRADS Capital, Endurance Investments & 12 others	47/100
7th	All G 2020, Waterloo (Australia), Series A	Developer of animal-free proteins using precision fermentation for nutrition applications	$36M	Dohler Ventures, Agronomics & 1 others	46/100
8th	Qualitas Health 2011, Jerusalem (Israel), Series A	Developer of algae-sourced omega-3 oils based food supplements and pharmaceutical ingredients	$22.5M	Gullspang Re Food, PeakBridge & 5 others	44/100
9th	Lactose India 1991, Ahmedabad (India), Public	Manufacturer of pharmaceutical excipients and dosage forms	-	-	44/100
10th	Angel Yeast 1986, Yichang (China), Public	Manufacturer of functional food ingredients	-	-	43/100